Findings seen with plant-based, low-fat diet with daily half cup of soybeans
WEDNESDAY, Oct. 26, 2022 (HealthDay News) — A plant-based, low-fat diet with daily soybeans significantly reduces the frequency and severity of postmenopausal hot flashes and associated symptoms, according to a study published online Oct. 18 in Menopause.
Neal D. Barnard, M.D., from the George Washington University School of Medicine & Health Sciences in Washington, D.C., and colleagues tested the effects of a dietary intervention on vasomotor symptoms and menopause-related quality of life. The analysis included 84 postmenopausal women reporting at least two moderate-to-severe hot flashes daily who were randomly assigned to an intervention of a low-fat, vegan diet and cooked soybeans (one half cup daily) or to a control group.
The researchers found that in the intervention group, moderate-to-severe hot flashes decreased by 88 percent versus 34 percent for the control group. Half of completers in the intervention group reported no moderate-to-severe hot flashes at 12 weeks, while among controls, there was no change from baseline. The intervention group also reported significant reductions in the Menopause-Specific Quality of Life questionnaire vasomotor, physical, and sexual domains.
“Our results mirror the diets of places in the world, like pre-Westernized Japan and modern-day Yucatán Peninsula, where a low-fat, plant-based diet including soybeans is more prevalent and where postmenopausal women experience fewer symptoms,” Barnard said in a statement.
Two authors disclosed financial ties to the pharmaceutical industry.
Estrogen Hormone Treatment May Be Beneficial for Brain Fog Symptoms in Menopausal Women
Menopausal Hormone Therapy Use Linked to Lower Risk for Alzheimer Disease
AMH Predicts Benefit of Chemo + Endocrine Therapy in Under 55s With Breast Cancer
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes
Add-On Tirzepatide May Reduce MACE Risk in People With T2D, ASCVD
Premature Menopause Linked to Increased Risk for Hypertension
Semaglutide Not Linked to Higher Neovascular Age-Related Macular Degeneration Risk